This text is a result of machine translation.
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Yesterday 12:13 PM
A fire broke out in a mechanical and electrical plant in Huaiyuan, Anhui Province, and local fire and public security departments are rescuing
Hong Kong Pharmaceutical stocks generally rose, with Cinda biology up nearly 6%
360 DigiTech: A Leader in an Oscillating Market
360 DigiTech's core competencies of asset-light model and technology focus offer a bright future. In the first quarter of 2022, the firm outperformed its competitors in terms of user amount, total loans granted and revenue. However, it operates in a market that has been performing below expectations as risks mount and profitability decreases.
Updated 2 hours ago
Hong Kong stocks continued to rise in the anti epidemic sector, and Junshi biology rose nearly 17%